nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—Vandetanib—thyroid cancer	0.179	0.386	CbGbCtD
Naloxone—CYP2C8—Sorafenib—thyroid cancer	0.0835	0.18	CbGbCtD
Naloxone—ABCB1—Sorafenib—thyroid cancer	0.0565	0.122	CbGbCtD
Naloxone—CYP3A4—Vandetanib—thyroid cancer	0.0562	0.121	CbGbCtD
Naloxone—ABCB1—Doxorubicin—thyroid cancer	0.0343	0.0739	CbGbCtD
Naloxone—CYP3A4—Sorafenib—thyroid cancer	0.0338	0.073	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—thyroid cancer	0.0205	0.0443	CbGbCtD
Naloxone—TLR4—thyroid gland—thyroid cancer	0.00918	0.153	CbGeAlD
Naloxone—CREB1—neck—thyroid cancer	0.00849	0.141	CbGeAlD
Naloxone—CREB1—saliva-secreting gland—thyroid cancer	0.00662	0.11	CbGeAlD
Naloxone—TLR4—lymph node—thyroid cancer	0.0057	0.0948	CbGeAlD
Naloxone—CREB1—thyroid gland—thyroid cancer	0.00404	0.0672	CbGeAlD
Naloxone—Rhinorrhoea—Sorafenib—thyroid cancer	0.00381	0.0378	CcSEcCtD
Naloxone—CREB1—head—thyroid cancer	0.00358	0.0596	CbGeAlD
Naloxone—ESR1—neck—thyroid cancer	0.00334	0.0556	CbGeAlD
Naloxone—Cardiac arrest—Vandetanib—thyroid cancer	0.00316	0.0313	CcSEcCtD
Naloxone—Nasopharyngitis—Vandetanib—thyroid cancer	0.00297	0.0295	CcSEcCtD
Naloxone—OPRD1—head—thyroid cancer	0.00283	0.0471	CbGeAlD
Naloxone—OPRK1—head—thyroid cancer	0.00272	0.0452	CbGeAlD
Naloxone—Depression—Vandetanib—thyroid cancer	0.00256	0.0253	CcSEcCtD
Naloxone—CREB1—lymph node—thyroid cancer	0.00251	0.0417	CbGeAlD
Naloxone—Cardiac disorder—Vandetanib—thyroid cancer	0.00214	0.0212	CcSEcCtD
Naloxone—Angiopathy—Vandetanib—thyroid cancer	0.00209	0.0207	CcSEcCtD
Naloxone—Mediastinal disorder—Vandetanib—thyroid cancer	0.00207	0.0205	CcSEcCtD
Naloxone—Mental disorder—Vandetanib—thyroid cancer	0.00202	0.02	CcSEcCtD
Naloxone—Nasopharyngitis—Sorafenib—thyroid cancer	0.00201	0.0199	CcSEcCtD
Naloxone—OPRM1—head—thyroid cancer	0.00193	0.0321	CbGeAlD
Naloxone—Tremor—Vandetanib—thyroid cancer	0.00188	0.0186	CcSEcCtD
Naloxone—Convulsion—Vandetanib—thyroid cancer	0.00174	0.0172	CcSEcCtD
Naloxone—Hypertension—Vandetanib—thyroid cancer	0.00173	0.0171	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00169	0.0168	CcSEcCtD
Naloxone—SLCO1A2—head—thyroid cancer	0.00166	0.0277	CbGeAlD
Naloxone—Nervous system disorder—Vandetanib—thyroid cancer	0.0016	0.0159	CcSEcCtD
Naloxone—ESR1—thyroid gland—thyroid cancer	0.00159	0.0264	CbGeAlD
Naloxone—Skin disorder—Vandetanib—thyroid cancer	0.00159	0.0157	CcSEcCtD
Naloxone—Paraesthesia—Vandetanib—thyroid cancer	0.00147	0.0145	CcSEcCtD
Naloxone—Dyspnoea—Vandetanib—thyroid cancer	0.00146	0.0144	CcSEcCtD
Naloxone—Flushing—Sorafenib—thyroid cancer	0.00144	0.0143	CcSEcCtD
Naloxone—Cardiac disorder—Sorafenib—thyroid cancer	0.00144	0.0143	CcSEcCtD
Naloxone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00141	0.014	CcSEcCtD
Naloxone—ESR1—head—thyroid cancer	0.00141	0.0235	CbGeAlD
Naloxone—Angiopathy—Sorafenib—thyroid cancer	0.00141	0.014	CcSEcCtD
Naloxone—Mediastinal disorder—Sorafenib—thyroid cancer	0.0014	0.0139	CcSEcCtD
Naloxone—Pain—Vandetanib—thyroid cancer	0.0014	0.0138	CcSEcCtD
Naloxone—Mental disorder—Sorafenib—thyroid cancer	0.00136	0.0135	CcSEcCtD
Naloxone—Abdominal pain—Vandetanib—thyroid cancer	0.00129	0.0128	CcSEcCtD
Naloxone—Body temperature increased—Vandetanib—thyroid cancer	0.00129	0.0128	CcSEcCtD
Naloxone—Asthenia—Vandetanib—thyroid cancer	0.00117	0.0116	CcSEcCtD
Naloxone—Hypertension—Sorafenib—thyroid cancer	0.00117	0.0116	CcSEcCtD
Naloxone—ALB—lymph node—thyroid cancer	0.00116	0.0193	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00114	0.0113	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00114	0.0113	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—thyroid cancer	0.00114	0.0112	CcSEcCtD
Naloxone—Diarrhoea—Vandetanib—thyroid cancer	0.00112	0.0111	CcSEcCtD
Naloxone—Nervous system disorder—Sorafenib—thyroid cancer	0.00108	0.0107	CcSEcCtD
Naloxone—Skin disorder—Sorafenib—thyroid cancer	0.00107	0.0106	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00106	0.0105	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—thyroid cancer	0.00105	0.0104	CcSEcCtD
Naloxone—Coma—Epirubicin—thyroid cancer	0.00104	0.0103	CcSEcCtD
Naloxone—Vomiting—Vandetanib—thyroid cancer	0.00104	0.0103	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—thyroid cancer	0.00102	0.0101	CcSEcCtD
Naloxone—ESR1—lymph node—thyroid cancer	0.000988	0.0164	CbGeAlD
Naloxone—Dyspnoea—Sorafenib—thyroid cancer	0.000983	0.00974	CcSEcCtD
Naloxone—Nausea—Vandetanib—thyroid cancer	0.000971	0.00962	CcSEcCtD
Naloxone—Coma—Doxorubicin—thyroid cancer	0.000966	0.00957	CcSEcCtD
Naloxone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000952	0.00943	CcSEcCtD
Naloxone—Pain—Sorafenib—thyroid cancer	0.000943	0.00934	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—thyroid cancer	0.000941	0.00932	CcSEcCtD
Naloxone—Hot flush—Epirubicin—thyroid cancer	0.000886	0.00878	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—thyroid cancer	0.000879	0.00871	CcSEcCtD
Naloxone—Abdominal pain—Sorafenib—thyroid cancer	0.000872	0.00864	CcSEcCtD
Naloxone—Body temperature increased—Sorafenib—thyroid cancer	0.000872	0.00864	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—thyroid cancer	0.00082	0.00813	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000813	0.00806	CcSEcCtD
Naloxone—ABCB1—trachea—thyroid cancer	0.000794	0.0132	CbGeAlD
Naloxone—Asthenia—Sorafenib—thyroid cancer	0.000791	0.00784	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—thyroid cancer	0.000788	0.00781	CcSEcCtD
Naloxone—Diarrhoea—Sorafenib—thyroid cancer	0.000754	0.00747	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—thyroid cancer	0.000741	0.00735	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—thyroid cancer	0.000729	0.00723	CcSEcCtD
Naloxone—Vomiting—Sorafenib—thyroid cancer	0.000701	0.00695	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000686	0.0068	CcSEcCtD
Naloxone—Nausea—Sorafenib—thyroid cancer	0.000655	0.00649	CcSEcCtD
Naloxone—ABCB1—thyroid gland—thyroid cancer	0.000628	0.0104	CbGeAlD
Naloxone—Sweating—Epirubicin—thyroid cancer	0.000613	0.00607	CcSEcCtD
Naloxone—Sweating—Doxorubicin—thyroid cancer	0.000567	0.00562	CcSEcCtD
Naloxone—ABCB1—head—thyroid cancer	0.000557	0.00927	CbGeAlD
Naloxone—Cardiac disorder—Epirubicin—thyroid cancer	0.000532	0.00527	CcSEcCtD
Naloxone—Flushing—Epirubicin—thyroid cancer	0.000532	0.00527	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—thyroid cancer	0.00052	0.00516	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—thyroid cancer	0.000517	0.00512	CcSEcCtD
Naloxone—Chills—Epirubicin—thyroid cancer	0.000515	0.0051	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—thyroid cancer	0.000502	0.00498	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—thyroid cancer	0.000493	0.00488	CcSEcCtD
Naloxone—Flushing—Doxorubicin—thyroid cancer	0.000493	0.00488	CcSEcCtD
Naloxone—Tension—Epirubicin—thyroid cancer	0.00049	0.00485	CcSEcCtD
Naloxone—Nervousness—Epirubicin—thyroid cancer	0.000485	0.0048	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—thyroid cancer	0.000481	0.00477	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000478	0.00474	CcSEcCtD
Naloxone—Chills—Doxorubicin—thyroid cancer	0.000476	0.00472	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—thyroid cancer	0.000465	0.00461	CcSEcCtD
Naloxone—Agitation—Epirubicin—thyroid cancer	0.000459	0.00455	CcSEcCtD
Naloxone—Tension—Doxorubicin—thyroid cancer	0.000453	0.00449	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—thyroid cancer	0.000449	0.00445	CcSEcCtD
Naloxone—Convulsion—Epirubicin—thyroid cancer	0.000433	0.00429	CcSEcCtD
Naloxone—Hypertension—Epirubicin—thyroid cancer	0.000431	0.00427	CcSEcCtD
Naloxone—Agitation—Doxorubicin—thyroid cancer	0.000425	0.00421	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000422	0.00418	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—thyroid cancer	0.0004	0.00397	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—thyroid cancer	0.0004	0.00396	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—thyroid cancer	0.000399	0.00395	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—thyroid cancer	0.000398	0.00394	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—thyroid cancer	0.000396	0.00392	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—thyroid cancer	0.000394	0.0039	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000391	0.00387	CcSEcCtD
Naloxone—ABCB1—lymph node—thyroid cancer	0.00039	0.00649	CbGeAlD
Naloxone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00037	0.00366	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—thyroid cancer	0.000368	0.00365	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—thyroid cancer	0.000366	0.00363	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—thyroid cancer	0.000366	0.00363	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000364	0.00361	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—thyroid cancer	0.000363	0.0036	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000352	0.00349	CcSEcCtD
Naloxone—Pain—Epirubicin—thyroid cancer	0.000348	0.00345	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—thyroid cancer	0.000339	0.00335	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—thyroid cancer	0.000336	0.00333	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000326	0.00323	CcSEcCtD
Naloxone—Pain—Doxorubicin—thyroid cancer	0.000322	0.00319	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—thyroid cancer	0.000322	0.00319	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—thyroid cancer	0.000322	0.00319	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—thyroid cancer	0.000298	0.00295	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—thyroid cancer	0.000298	0.00295	CcSEcCtD
Naloxone—Asthenia—Epirubicin—thyroid cancer	0.000292	0.0029	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—thyroid cancer	0.000279	0.00276	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—thyroid cancer	0.000271	0.00268	CcSEcCtD
Naloxone—Vomiting—Epirubicin—thyroid cancer	0.000259	0.00257	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—thyroid cancer	0.000258	0.00256	CcSEcCtD
Naloxone—Nausea—Epirubicin—thyroid cancer	0.000242	0.0024	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—thyroid cancer	0.00024	0.00238	CcSEcCtD
Naloxone—Nausea—Doxorubicin—thyroid cancer	0.000224	0.00222	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—TSHR—thyroid cancer	0.000123	0.000327	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TSHR—thyroid cancer	0.000122	0.000326	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000122	0.000325	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—AKT1—thyroid cancer	0.000122	0.000325	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000121	0.000322	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PRKAR1A—thyroid cancer	0.00012	0.000321	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—KRAS—thyroid cancer	0.000119	0.000318	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—SST—thyroid cancer	0.000119	0.000318	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—TPR—thyroid cancer	0.000119	0.000316	CbGpPWpGaD
Naloxone—CREB1—Disease—CDK1—thyroid cancer	0.000119	0.000316	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PRKAR1A—thyroid cancer	0.000117	0.000311	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000117	0.000311	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000116	0.000311	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MEN1—thyroid cancer	0.000116	0.00031	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000116	0.000309	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MEN1—thyroid cancer	0.000115	0.000307	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000115	0.000307	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MEN1—thyroid cancer	0.000115	0.000306	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CALCA—thyroid cancer	0.000115	0.000306	CbGpPWpGaD
Naloxone—TLR4—Immune System—KRAS—thyroid cancer	0.000114	0.000303	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	0.00011	0.000294	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CHST14—thyroid cancer	0.00011	0.000293	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	0.00011	0.000292	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000108	0.000289	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000108	0.000289	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—KRAS—thyroid cancer	0.000108	0.000288	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000108	0.000288	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TSHR—thyroid cancer	0.000107	0.000286	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000107	0.000285	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000106	0.000282	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000105	0.000281	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTCH1—thyroid cancer	0.000104	0.000278	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTCH1—thyroid cancer	0.000104	0.000277	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CDK1—thyroid cancer	0.000104	0.000277	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—HRAS—thyroid cancer	0.000104	0.000276	CbGpPWpGaD
Naloxone—CREB1—Immune System—NRG1—thyroid cancer	0.000103	0.000275	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	0.000102	0.000272	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HPGD—thyroid cancer	0.000102	0.000271	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—HRAS—thyroid cancer	0.000101	0.000271	CbGpPWpGaD
Naloxone—ALB—Metabolism—HPGD—thyroid cancer	0.000101	0.000269	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MEN1—thyroid cancer	0.000101	0.000269	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.0001	0.000268	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	9.78e-05	0.000261	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	9.73e-05	0.000259	CbGpPWpGaD
Naloxone—TLR4—Immune System—HRAS—thyroid cancer	9.66e-05	0.000257	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	9.6e-05	0.000256	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SST—thyroid cancer	9.53e-05	0.000254	CbGpPWpGaD
Naloxone—CREB1—Disease—NRG1—thyroid cancer	9.52e-05	0.000254	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SST—thyroid cancer	9.5e-05	0.000253	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IFNA2—thyroid cancer	9.32e-05	0.000248	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.27e-05	0.000247	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—HRAS—thyroid cancer	9.18e-05	0.000245	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CALCA—thyroid cancer	9.18e-05	0.000245	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CALCA—thyroid cancer	9.15e-05	0.000244	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTCH1—thyroid cancer	9.11e-05	0.000243	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TSHR—thyroid cancer	9.05e-05	0.000241	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—AKT1—thyroid cancer	8.96e-05	0.000239	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—NRAS—thyroid cancer	8.96e-05	0.000239	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRKAR1A—thyroid cancer	8.91e-05	0.000238	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—SLC5A5—thyroid cancer	8.88e-05	0.000237	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—PTEN—thyroid cancer	8.87e-05	0.000236	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HPGD—thyroid cancer	8.84e-05	0.000236	CbGpPWpGaD
Naloxone—CREB1—Disease—TERT—thyroid cancer	8.55e-05	0.000228	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	8.53e-05	0.000228	CbGpPWpGaD
Naloxone—TLR4—Immune System—AKT1—thyroid cancer	8.53e-05	0.000227	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—PTEN—thyroid cancer	8.51e-05	0.000227	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MEN1—thyroid cancer	8.51e-05	0.000227	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MINPP1—thyroid cancer	8.46e-05	0.000225	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SST—thyroid cancer	8.33e-05	0.000222	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.32e-05	0.000222	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDK1—thyroid cancer	8.31e-05	0.000221	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDK1—thyroid cancer	8.28e-05	0.000221	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.23e-05	0.00022	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.19e-05	0.000218	CbGpPWpGaD
Naloxone—CREB1—Disease—HIF1A—thyroid cancer	8.17e-05	0.000218	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.12e-05	0.000216	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	8.11e-05	0.000216	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TSHR—thyroid cancer	8.03e-05	0.000214	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CALCA—thyroid cancer	8.02e-05	0.000214	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NRAS—thyroid cancer	7.91e-05	0.000211	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	7.9e-05	0.000211	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.79e-05	0.000208	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—RXRA—thyroid cancer	7.77e-05	0.000207	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.71e-05	0.000206	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—KRAS—thyroid cancer	7.71e-05	0.000206	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTCH1—thyroid cancer	7.7e-05	0.000205	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NRAS—thyroid cancer	7.6e-05	0.000203	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MEN1—thyroid cancer	7.55e-05	0.000201	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—RXRA—thyroid cancer	7.46e-05	0.000199	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.44e-05	0.000198	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDK1—thyroid cancer	7.26e-05	0.000194	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.26e-05	0.000194	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	7.19e-05	0.000192	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SST—thyroid cancer	7.04e-05	0.000188	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTCH1—thyroid cancer	6.83e-05	0.000182	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.82e-05	0.000182	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—KRAS—thyroid cancer	6.81e-05	0.000182	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CALCA—thyroid cancer	6.78e-05	0.000181	CbGpPWpGaD
Naloxone—CREB1—Disease—BRAF—thyroid cancer	6.77e-05	0.000181	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CHST14—thyroid cancer	6.76e-05	0.00018	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRG1—thyroid cancer	6.67e-05	0.000178	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRG1—thyroid cancer	6.65e-05	0.000177	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—HRAS—thyroid cancer	6.55e-05	0.000175	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KRAS—thyroid cancer	6.54e-05	0.000174	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SST—thyroid cancer	6.24e-05	0.000166	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDK1—thyroid cancer	6.14e-05	0.000164	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CALCA—thyroid cancer	6.01e-05	0.00016	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TERT—thyroid cancer	5.99e-05	0.00016	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TERT—thyroid cancer	5.97e-05	0.000159	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TPR—thyroid cancer	5.83e-05	0.000155	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRG1—thyroid cancer	5.83e-05	0.000155	CbGpPWpGaD
Naloxone—ALB—Metabolism—TPR—thyroid cancer	5.8e-05	0.000155	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—thyroid cancer	5.79e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—AKT1—thyroid cancer	5.79e-05	0.000154	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	5.74e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HIF1A—thyroid cancer	5.72e-05	0.000153	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.71e-05	0.000152	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HIF1A—thyroid cancer	5.71e-05	0.000152	CbGpPWpGaD
Naloxone—ALB—Metabolism—PRKAR1A—thyroid cancer	5.7e-05	0.000152	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—thyroid cancer	5.56e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—thyroid cancer	5.47e-05	0.000146	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HPGD—thyroid cancer	5.45e-05	0.000145	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDK1—thyroid cancer	5.44e-05	0.000145	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TERT—thyroid cancer	5.23e-05	0.00014	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.2e-05	0.000139	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.17e-05	0.000138	CbGpPWpGaD
Naloxone—CREB1—Immune System—PTEN—thyroid cancer	5.16e-05	0.000138	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—AKT1—thyroid cancer	5.11e-05	0.000136	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TPR—thyroid cancer	5.08e-05	0.000135	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.08e-05	0.000135	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—NRAS—thyroid cancer	5.04e-05	0.000134	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—NRAS—thyroid cancer	5.03e-05	0.000134	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HIF1A—thyroid cancer	5e-05	0.000133	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PRKAR1A—thyroid cancer	5e-05	0.000133	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRG1—thyroid cancer	4.92e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—AKT1—thyroid cancer	4.91e-05	0.000131	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—PPARG—thyroid cancer	4.9e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Disease—PTEN—thyroid cancer	4.77e-05	0.000127	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—BRAF—thyroid cancer	4.74e-05	0.000126	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—BRAF—thyroid cancer	4.73e-05	0.000126	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PPARG—thyroid cancer	4.71e-05	0.000126	CbGpPWpGaD
Naloxone—CREB1—Immune System—NRAS—thyroid cancer	4.61e-05	0.000123	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TERT—thyroid cancer	4.42e-05	0.000118	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—NRAS—thyroid cancer	4.41e-05	0.000118	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRG1—thyroid cancer	4.37e-05	0.000116	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC5A5—thyroid cancer	4.36e-05	0.000116	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	4.36e-05	0.000116	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—thyroid cancer	4.34e-05	0.000116	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC5A5—thyroid cancer	4.34e-05	0.000116	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—thyroid cancer	4.33e-05	0.000115	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.29e-05	0.000114	CbGpPWpGaD
Naloxone—CREB1—Disease—NRAS—thyroid cancer	4.25e-05	0.000113	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HIF1A—thyroid cancer	4.23e-05	0.000113	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—BRAF—thyroid cancer	4.14e-05	0.00011	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.09e-05	0.000109	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.07e-05	0.000108	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—thyroid cancer	3.97e-05	0.000106	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TERT—thyroid cancer	3.92e-05	0.000105	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC5A5—thyroid cancer	3.8e-05	0.000101	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—thyroid cancer	3.79e-05	0.000101	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HIF1A—thyroid cancer	3.75e-05	0.0001	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NRAS—thyroid cancer	3.73e-05	9.93e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—thyroid cancer	3.71e-05	9.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—thyroid cancer	3.69e-05	9.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—thyroid cancer	3.68e-05	9.81e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—RXRA—thyroid cancer	3.67e-05	9.78e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—thyroid cancer	3.66e-05	9.76e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—RXRA—thyroid cancer	3.65e-05	9.72e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—thyroid cancer	3.58e-05	9.54e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.57e-05	9.51e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.55e-05	9.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—thyroid cancer	3.5e-05	9.34e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—thyroid cancer	3.48e-05	9.27e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—thyroid cancer	3.46e-05	9.22e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—thyroid cancer	3.45e-05	9.2e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—thyroid cancer	3.37e-05	8.99e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—thyroid cancer	3.34e-05	8.9e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—thyroid cancer	3.33e-05	8.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—thyroid cancer	3.26e-05	8.69e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—thyroid cancer	3.25e-05	8.66e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—thyroid cancer	3.23e-05	8.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—thyroid cancer	3.22e-05	8.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—thyroid cancer	3.21e-05	8.55e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RXRA—thyroid cancer	3.19e-05	8.52e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—thyroid cancer	3.14e-05	8.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TPR—thyroid cancer	3.13e-05	8.35e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—thyroid cancer	3.11e-05	8.3e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—thyroid cancer	3.1e-05	8.28e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.08e-05	8.21e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—thyroid cancer	3.02e-05	8.06e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—thyroid cancer	2.99e-05	7.98e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—thyroid cancer	2.98e-05	7.94e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—thyroid cancer	2.98e-05	7.94e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—thyroid cancer	2.97e-05	7.92e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—thyroid cancer	2.92e-05	7.78e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—thyroid cancer	2.85e-05	7.59e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—thyroid cancer	2.75e-05	7.33e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—thyroid cancer	2.73e-05	7.27e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—thyroid cancer	2.66e-05	7.09e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—thyroid cancer	2.65e-05	7.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—thyroid cancer	2.6e-05	6.94e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—thyroid cancer	2.56e-05	6.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—thyroid cancer	2.56e-05	6.82e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—thyroid cancer	2.56e-05	6.81e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—thyroid cancer	2.54e-05	6.78e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—thyroid cancer	2.47e-05	6.58e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—thyroid cancer	2.41e-05	6.42e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.34e-05	6.25e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—thyroid cancer	2.32e-05	6.17e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—thyroid cancer	2.3e-05	6.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—thyroid cancer	2.28e-05	6.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—thyroid cancer	2.27e-05	6.06e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—thyroid cancer	2.27e-05	6.04e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—thyroid cancer	2.25e-05	5.99e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—thyroid cancer	2.24e-05	5.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—thyroid cancer	2.2e-05	5.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—thyroid cancer	2.19e-05	5.83e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—thyroid cancer	2.18e-05	5.81e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—thyroid cancer	2.17e-05	5.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—thyroid cancer	2.02e-05	5.38e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—thyroid cancer	1.99e-05	5.31e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RXRA—thyroid cancer	1.97e-05	5.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—thyroid cancer	1.95e-05	5.2e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—thyroid cancer	1.94e-05	5.17e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—thyroid cancer	1.92e-05	5.13e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—thyroid cancer	1.92e-05	5.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—thyroid cancer	1.91e-05	5.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—thyroid cancer	1.89e-05	5.05e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—thyroid cancer	1.86e-05	4.97e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.82e-05	4.86e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—thyroid cancer	1.81e-05	4.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—thyroid cancer	1.68e-05	4.49e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—thyroid cancer	1.68e-05	4.49e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—thyroid cancer	1.68e-05	4.48e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—thyroid cancer	1.61e-05	4.29e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—thyroid cancer	1.59e-05	4.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—thyroid cancer	1.59e-05	4.23e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—thyroid cancer	1.58e-05	4.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—thyroid cancer	1.49e-05	3.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—thyroid cancer	1.43e-05	3.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—thyroid cancer	1.42e-05	3.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—thyroid cancer	1.38e-05	3.69e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—thyroid cancer	1.26e-05	3.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—thyroid cancer	1.24e-05	3.31e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.78e-06	2.61e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—thyroid cancer	9.15e-06	2.44e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—thyroid cancer	9.1e-06	2.43e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—thyroid cancer	8.53e-06	2.27e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—thyroid cancer	7.98e-06	2.13e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—thyroid cancer	4.91e-06	1.31e-05	CbGpPWpGaD
